Colin Walsh Purchases 500,000 Shares of Attovia Therapeutics (NASDAQ:ATTO) Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) Director Colin Walsh acquired 500,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $8,500,000.00. Following the completion of the transaction, the director directly owned 3,020,632 shares in the company, valued at approximately $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Colin Walsh also recently made the following trade(s):

• On Wednesday, August 5th, Colin Walsh bought 85,000 shares of Attovia Therapeutics stock. The stock was purchased at an average cost of $21.00 per share, with a total value of $1,785,000.00.
• On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The stock was sold at an average price of $21.28, for a total transaction of $2,251,572.96.

Attovia Therapeutics Stock Up 3.5%

Shares of ATTO stock opened at $19.86 on Friday. Attovia Therapeutics, Inc. has a 52-week low of $16.15 and a 52-week high of $22.79.

Institutional Trading of Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. boosted its holdings in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.